



SK Life Science, Inc. Announces Campaign to Support Patient Recruitment in Ongoing Global Study for Adolescents Living with Primary Generalized Tonic-Clonic (PGTC) Seizures

Paramus, NJ, July 31, 2024 – [SK Life Science, Inc.](#), a U.S. pharmaceutical company developing treatments for central nervous system (CNS) disorders and a subsidiary of [SK Biopharmaceuticals, Co., Ltd.](#), recently launched a campaign to recruit patients for a Phase 3 global randomized, double-blind, placebo-controlled, multicenter study for pediatric patients between 12 and 17 years of age who continue to have primary generalized tonic-clonic (PGTC) seizures despite taking traditional medications. This campaign aims to support the completion of enrollment for this study, which was launched in 2020, and is part of SK Life Science’s intensified efforts and ongoing commitment to CNS and seizure disorders.

“I have witnessed the profound impact that breakthrough seizures can have on the lives of children and teenagers,” said Dr. Sunita Misra, M.D., Ph.D., VP of Global Clinical Development and acting Chief Medical Officer at SK Life Science. “At SK Life Science, we are recruiting patients diagnosed with PGTC seizures for a comprehensive global study spanning multiple locations across twelve states in the United States and sites in Australia, Hungary, Poland, Slovakia, South Korea, and Spain.”

Active study sites in the U.S. are located in Arizona, Colorado, Georgia, Maryland, Minnesota, Missouri, New Jersey, North Carolina, Ohio, Tennessee, Texas, and Utah. For more information about the PGTC seizures study and site locations, please visit <https://pgtcseizurestudy.com/>.

Media Contact:

Dina Albanese
media@sklsi.com

###

About Epilepsy

Epilepsy is the fourth most common neurological disorder. There are approximately 3.4 million people living with epilepsy in the United States, with 150,000 new cases each year in the country.^{1,2} Epilepsy is characterized by recurrent, unprovoked seizures. The seizures in epilepsy may be related to a brain injury or a family tendency, but often the cause is completely unknown. Having seizures and epilepsy can affect one's safety, relationships, work, driving, and much more.^{3,4} People with epilepsy are at risk for accidents and other health complications, including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP).^{3,4} Despite the availability of many antiepileptic therapies, almost 40 percent of people with epilepsy are not able to achieve seizure freedom, meaning they have epilepsy that remains uncontrolled.⁵

About Epilepsy in Children

Epilepsy is the most common serious neurological disorder in children.⁶ About 470,000 children under the age of 14 have epilepsy in the United States. While for many children epilepsy can be controlled with

currently available medication, for others, epilepsy may be a lifelong challenge affecting many areas of life. The social impact in childhood is often severe, producing isolation and loss of self-esteem.⁷

About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.

SK Biopharmaceuticals and its U.S. subsidiary SK Life Science are pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin their expansion into oncology through research and development efforts. The companies have a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at www.skbp.com/eng and SK Life Science's website at www.SKLifeScienceInc.com.

Both SK Biopharmaceuticals and SK Life Science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit <https://sk-inc.com/en/main/mainpage.aspx>.

References

1. Epilepsy Foundation. Who Can Get Epilepsy? <https://www.epilepsy.com/learn/about-epilepsy-basics/who-gets-epilepsy>. Accessed July 2024.
2. Epilepsy Foundation. Facts & Statistics About Epilepsy. <https://www.epilepsy.com/learn/about-epilepsy-basics/epilepsy-statistics>. Accessed July 2024.
3. Epilepsy Foundation. Staying Safe. <https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe>. Accessed July 2024.
4. Epilepsy Foundation. Complications and Risks. <https://www.epilepsy.com/learn/challenges-epilepsy>. Accessed July 2024.
5. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. <https://www.ncbi.nlm.nih.gov/pubmed/29279892>. Published online December 26, 2017.
6. Epilepsies in children and young people: investigative procedures and management: a national clinical guideline. Edinburgh, Scotland: SIGN; 2020. (SIGN Publication no. 159). (May 2021). Available <http://resource.nlm.nih.gov/9918334378406676>.
7. Epilepsy Foundation. Epilepsy in Childhood. <https://www.epilepsy.com/parents-and-caregivers/kids>. Accessed July 2024.